Warren D. Marcus

Dr. Warren Marcus received his bachelor’s degree from MIT in 1995 and performed his doctoral work at Duke University, where he received his PhD in 2000. He then performed postdoctoral research at the Georgia Institute of Technology until 2002, and was then a researcher at Arizona State University until 2006. He left academia and started to work at Altor Bioscience in 2006, where he was an inventor of an FDA approved drug (April 2024) now known as Anktiva. While initially spending the first 5 years primarily in the lab, during his final 7 years at Altor, Dr. Marcus was involved in the business development of the company, actively looking for investors and pharmaceutical partners for the company/drug. After a short stint as a director of business development and research at a small diagnostic company, Dr. Marcus joined a large, international pharmaceutical company: Boehringer Ingelheim. While at BI, Dr. Marcus was helping the business development team to scout startup biotechs, which was in line with his goals of starting a biotech company. Thus after a thorough search, Dr. Marcus found some revolutionary RNA technology for diabetes at the University of Miami, leading to him in-licensing the technology into Wink Biotherapeutics.